Quarterly Financial Summary (For the first nine months of the fiscal year ending March 31, 2021) [Under Japanese GAAP] (Consolidated)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: First Section of Tokyo Stock Exchange)

Code Number: 4559 (URL: https://www.zeria.co.jp/)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division TEL (03) 3661-1039

Scheduled date to submit the Quarterly Securities Report: February 9, 2021

Scheduled date to commence dividend payments:

Preparation of supplementary documents to the quarterly financial results:

None

Holding of quarterly financial results presentation: None

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2020 through December 31, 2020)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Nine months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
December 31, 2020	42,374	(8.5)	3,856	14.0	3,538	14.6	3,686	57.5
December 31, 2019	46,303	(1.9)	3,382	10.5	3,086	9.5	2,339	(19.3)

Note: Comprehensive income: For the nine months ended December 31, 2020: 3,985 million yen [579.9%] For the nine months ended December 31, 2019: 586 million yen [(63.5)%]

	Basic earnings	Diluted earnings per share		
	per share			
Nine months ended	Yen	Yen		
December 31, 2020	79.83	-		
December 31, 2019	49.98	_		

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share	
As of	Million yen	Million yen	%	Yen	
December 31, 2020	119,940	54,427	45.2	1,180.93	
March 31, 2020	104,155	52,678	50.4	1,134.30	

Reference: Equity: As of December 31, 2020: 54,266 million yen

As of March 31, 2020: 52,510 million yen

2. Dividends

2. Dividends	Annual dividends						
	First quarter	Second quarter	Third quarter	Year-end	Total		
	Yen	Yen	Yen	Yen	Yen		
Year ended March 31, 2020	-	17.00	_	17.00	34.00		
Year ending March 31, 2021	-	17.00	_				
Year ending March 31, 2021 (Forecast)				17.00	34.00		

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2021 (April 1, 2020 through March 31, 2021)

(Percentage figures indicate year-on-year changes.)

	Net sales		Operating p	rofit	fit Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	57,500	(4.8)	4,300	5.0	3,900	0.5	3,700	26.5	80.23

Note: Revision of the financial forecast most recently announced: Yes

* Notes

(1) Significant changes of subsidiaries during the nine months ended December 31, 2020 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

- (2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes
- (3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections
 - 1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
 - 2) Changes in accounting policies due to other reasons: None
 - 3) Changes in accounting estimates: None
 - 4) Restatement of prior period financial statements after error corrections: None
- (4) Number of shares issued (common shares)
 - 1) Number of shares issued as of the end of the period (including treasury shares):
 As of December 31, 2020: 53,119,190 shares
 As of March 31, 2020: 53,119,190 shares
 - 2) Number of treasury shares as of the end of the period:

As of December 31, 2020: 7,166,340 shares

As of March 31, 2020: 6,825,944 shares

3) Average number of shares during the period (cumulative from the beginning of the fiscal year):

For the nine months ended December 31, 2020: 46,174,949 shares

For the nine months ended December 31, 2019: 46,820,994 shares

- * Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or An Audit Corporation.
- * Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.